ANZGOG’s gynaecological cancer clinical trials are conducted cooperatively by multidisciplinary teams of researchers.
More than 50 hospitals in Australia and New Zealand are recruiting participants to ANZGOG clinical trials in ovarian, endometrial, and cervical cancer.
Many of our trials are developed and led by ANZGOG members, others are part of an international collaboration where ANZGOG leads the Australian and New Zealand operations. In this way we are able to offer a wide range of trials and fast-track new treatments for women in Australia and New Zealand.
All clinical trials recruiting patients in Australia and New Zealand can be found on the Australia New Zealand Clinical Trials Registry
Gynaecological cancer clinical trials currently recruiting
A multicentre phase II randomised trial of durvalumab (MEDI4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas.
A phase II signal-seeking trial of adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with cyclin E1 (CCNE1) over-expression with and without gene amplification.
STICs AND STONEs
A randomised phase II double-blind placebo-controlled trial of acetylsalicylic acid (ASA) in prevention of ovarian cancer in women with BRCA 1 and 2 mutations.
A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.
Testing individual interventions to optimize perioperative care in ovarian cancer surgery.
A Phase II, signal-seeking trial of the clinical benefit rate associated with pamiparib in subjects with germline or somatic BRCA1/2 high grade serous ovarian cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the presence of an ABCB1 fusion and the absence of a BRCA1/2 reversion
A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”.
A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2).
A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first-line treatment for ovarian cancer.
A Phase III randomised study to evaluate the efficacy of maintenance therapy with olapraib and cediranib or olaparib alone in patients with relapsed ovarian cancer following a response to platinum-based chemotherapy
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer.
The NEO study has been funded through ANZGOG’s Fund for New Research. It is led by Auckland District Hospital Board New Zealand.
Identifying factors which predict for health-related quality of life deficits and increased symptom burden in women who have been treated for endometrial cancer.
Phase III double-blind randomised placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
A Phase II Randomised Clinical Trial of Mirena® ± Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium.
Excisional treatment in women with cervical adenocarcinoma-in-situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure to cold knife cone biopsy.
The pilot of the EXCISE trial has been funded through ANZGOG’s Fund for New Research. It is led by the St John of God Subiaco Hospital.